AMIX

Autonomix Medical Inc. (AMIX) | Rumor.io

Autonomix Medical

AMIX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,060

Bullish sentiment (50-day avg)82%

Price to earnings ratio-0.08

Market capitalization7.5M

Earnings per share-31.1

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-16.7M

Social

What share of all stock conversation is about AMIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% -0.02	0% +0

Aug 26

Autonomix Medical's stock price has experienced significant fluctuations, with some traders expressing disappointment in the company's performance and others questioning the value of their investment.
The company's need for additional financing to achieve commercialization, estimated to be around $25-30 million, has raised concerns among shareholders about potential dilution and the impact on their investments.
Autonomix Medical's stock price has experienced a decline, with some traders speculating about the company's future prospects and the potential for further cash raises and associated price pops.

Generated by AI

Sentiment

Of the messages about AMIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +18.24	80.15% -4.24
Bearish	—	—	0% -18.24	19.85% +4.24

Bullish· Aug 25

The company has a strong catalyst ahead with fresh capital coming into the company, which could lead to a significant move.
The low float and upcoming patent news could send the stock price over $10, making it a promising investment opportunity.
The shorts are likely to shut their mouths once the stock price surpasses $10, as the strong fundamentals and catalysts are expected to drive the price up.

Bearish· Aug 25

The company's repeated patent news announcements may be a scheme to distract from its true financial struggles, potentially leading to a sharp decline in value.
The company's warrant releases may be poorly timed, causing a surge in selling and a subsequent drop in price, potentially leading to a value of $5.12 or lower.
The asset's recent spike to $8 may be a trap to lure investors in, followed by a significant drop in price, potentially to sub $7 or even sub $5 by the end of the week.

Generated by AI

Topics

Of the messages about AMIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	18.13%
Technical Analysis	—	—	0%	19.28%
Analysts	—	—	0%	33.33%
Macro	—	—	0%	29%
Controversies	—	—	0%	0.19%
Earnings	—	—	0%	0.07%

Aug 4

The technical setup for $AMIX is getting interesting, with the $16-$17 zone acting as a key pivot area and bulls needing to defend this level to prove demand is still there.
A clean break and hold above $20 could open the door for another attempt at the 2024/2025 highs, while a loss of $10.00 would be the first clear sign of exhaustion in the price action.
The breakout above $7 and continued strength beyond that level is necessary for $AMIX to be considered a strong momentum name, with a decisive breakout above $7.30 potentially opening the door to further upside.

Generated by AI

Community

Of the messages about AMIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	17.14%	19.85%
Newcomers	—	100%	82.86%	80.15%

Regulars· Aug 25

The company recently did an after-hours offering, which may have killed the momentum of a 60% price move from $10 to $16.41.
The remaining warrant shares may be absorbed by the market tomorrow, and the price may drop further in the morning.
The stock price is currently drifting, and a break above local resistance in the 8.50s could lead to a retest of yesterday's supply ranges.

Newcomers· Aug 26

AMIX is expected to need another $25–30M in financing to bring its first product to commercialization, not expected until around 2029/2030.
The company's history of dilution is a major concern for shareholders, with the potential for substantial dilution through new share issuance to fund salaries, operations, and research.
Despite having interesting technology, AMIX has been a money-losing machine for long-term shareholders, with repeated dilution of their investments through warrant deals and reverse splits.

Generated by AI

News

Autonomix Medical receives European patent for neural assessment technology

5d agoInvesting.com

Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform

5d agoYahoo Finance

Autonomix Medical appoints Sandra Cohen Kalter to board

13d agoInvesting.com

Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors

Autonomix Medical, Inc. Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies THE WOODLANDS, TX, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to a

13d agoYahoo Finance

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Abstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two scientific abstracts have been accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2

28d agoYahoo Finance

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain THE WOODLANDS, TX, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,714,780 by the United States Patent a

1mo agoYahoo Finance

Also Discussed

Investors talking about AMIX also mention

#	Name	Attention
1	Nocera, Inc.NCRA	0%new
2	TNL Mediagene Ordinary SharesTNMG	0%new
3	Advanced Biomed Inc.ADVB	0%0
4	Inno Holdings Inc.INHD	0%new
5	T3 Defense Inc.DFNS	0%+0
6	Zhongchao Inc. Class A Ordinary SharesZCMD	0%new
7	Baiya International Group Inc. Class A Ordinary SharesBIYA	0%new
8	SciSparc Ltd.SPRC	0%+0
9	Yunji Inc.YJ	0%new
10	Stak Inc. Class A Ordinary SharesSTAK	0%0

Autonomix Medical Inc.

Healthcare
Medical Devices

Autonomix Medical Inc. is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its current platform centers on a catheter-based, microchip-enabled sensing array designed to detect and differentiate neural signals with high sensitivity from within the vascular system. The company is developing this technology for applications in pancreatic cancer and pancreatitis, while also addressing areas such as chronic pain management, hypertension, cardiovascular conditions, and other nerve-related disorders. Autonomix Medical Inc. operates as a single-segment business dedicated to improving how neural conditions are diagnosed and treated through minimally invasive, signal-detection-based tools. Headquartered in The Woodlands, Texas, Autonomix Medical Inc. serves the medical technology market with a specialized focus on nerve-targeted interventions and disease management.

Website

Location

21 Waterway Avenue

The Woodlands, TX, 77380

United States

Social

What share of all stock conversation is about AMIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% -0.02	0% +0

Aug 26

Autonomix Medical's stock price has experienced significant fluctuations, with some traders expressing disappointment in the company's performance and others questioning the value of their investment.
The company's need for additional financing to achieve commercialization, estimated to be around $25-30 million, has raised concerns among shareholders about potential dilution and the impact on their investments.
Autonomix Medical's stock price has experienced a decline, with some traders speculating about the company's future prospects and the potential for further cash raises and associated price pops.

Generated by AI

Sentiment

Of the messages about AMIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +18.24	80.15% -4.24
Bearish	—	—	0% -18.24	19.85% +4.24

Bullish· Aug 25

The company has a strong catalyst ahead with fresh capital coming into the company, which could lead to a significant move.
The low float and upcoming patent news could send the stock price over $10, making it a promising investment opportunity.
The shorts are likely to shut their mouths once the stock price surpasses $10, as the strong fundamentals and catalysts are expected to drive the price up.

Bearish· Aug 25

The company's repeated patent news announcements may be a scheme to distract from its true financial struggles, potentially leading to a sharp decline in value.
The company's warrant releases may be poorly timed, causing a surge in selling and a subsequent drop in price, potentially leading to a value of $5.12 or lower.
The asset's recent spike to $8 may be a trap to lure investors in, followed by a significant drop in price, potentially to sub $7 or even sub $5 by the end of the week.

Generated by AI

Topics

Of the messages about AMIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	18.13%
Technical Analysis	—	—	0%	19.28%
Analysts	—	—	0%	33.33%
Macro	—	—	0%	29%
Controversies	—	—	0%	0.19%
Earnings	—	—	0%	0.07%

Aug 4

The technical setup for $AMIX is getting interesting, with the $16-$17 zone acting as a key pivot area and bulls needing to defend this level to prove demand is still there.
A clean break and hold above $20 could open the door for another attempt at the 2024/2025 highs, while a loss of $10.00 would be the first clear sign of exhaustion in the price action.
The breakout above $7 and continued strength beyond that level is necessary for $AMIX to be considered a strong momentum name, with a decisive breakout above $7.30 potentially opening the door to further upside.

Generated by AI

Community

Of the messages about AMIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	17.14%	19.85%
Newcomers	—	100%	82.86%	80.15%

Regulars· Aug 25

The company recently did an after-hours offering, which may have killed the momentum of a 60% price move from $10 to $16.41.
The remaining warrant shares may be absorbed by the market tomorrow, and the price may drop further in the morning.
The stock price is currently drifting, and a break above local resistance in the 8.50s could lead to a retest of yesterday's supply ranges.

Newcomers· Aug 26

AMIX is expected to need another $25–30M in financing to bring its first product to commercialization, not expected until around 2029/2030.
The company's history of dilution is a major concern for shareholders, with the potential for substantial dilution through new share issuance to fund salaries, operations, and research.
Despite having interesting technology, AMIX has been a money-losing machine for long-term shareholders, with repeated dilution of their investments through warrant deals and reverse splits.

Generated by AI

Autonomix Medical

Social

Aug 26

Bullish· Aug 25

Bearish· Aug 25

Aug 4

Regulars· Aug 25

Newcomers· Aug 26

Autonomix Medical receives European patent for neural assessment technology

Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform

Autonomix Medical appoints Sandra Cohen Kalter to board

Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

Also Discussed

Autonomix Medical Inc.

Company Information

Location

Social

Aug 26

Bullish· Aug 25

Bearish· Aug 25

Aug 4

Regulars· Aug 25

Newcomers· Aug 26

Autonomix Medical receives European patent for neural assessment technology

Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform

Autonomix Medical appoints Sandra Cohen Kalter to board

Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

Also Discussed